Surat – Pneumococcal Disease and Prevention (11th March 2021)
2 replies on “Surat – Pneumococcal Disease and Prevention (11th March 2021)”
Why the PNEUMOSIL don’t have 3+1 recommendations in their product insert if the product is having all the trials in 3+1 schedule, then why it is mention at the of 6,10 & 14 weeks only why not at 15-18 months is mentioned in the product insert, if the product can have all trials data in their product insert then why 3+1 can’t mentioned directly in their PI
DIAP India
2 replies on “Surat – Pneumococcal Disease and Prevention (11th March 2021)”
Why the PNEUMOSIL don’t have 3+1 recommendations in their product insert if the product is having all the trials in 3+1 schedule, then why it is mention at the of 6,10 & 14 weeks only why not at 15-18 months is mentioned in the product insert, if the product can have all trials data in their product insert then why 3+1 can’t mentioned directly in their PI
Good afternoon sir